Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone720-696-8100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.52 million
Profitability
Miscellaneous
Employees67
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions
What is Viveve Medical's stock symbol?
Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."
How were Viveve Medical's earnings last quarter?
Viveve Medical Inc (NASDAQ:VIVE) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($21.00) EPS for the quarter, missing the Zacks' consensus estimate of ($18.00) by $3.00. The firm earned $1.05 million during the quarter, compared to the consensus estimate of $3.92 million. Viveve Medical had a negative net margin of 341.01% and a negative return on equity of 2,976.15%. View Viveve Medical's Earnings History.
When is Viveve Medical's next earnings date?
What price target have analysts set for VIVE?
6 Wall Street analysts have issued 12 month price objectives for Viveve Medical's stock. Their predictions range from $0.20 to $6.00. On average, they anticipate Viveve Medical's stock price to reach $2.24 in the next twelve months. This suggests that the stock has a possible downside of 56.0%. View Analyst Price Targets for Viveve Medical.
What is the consensus analysts' recommendation for Viveve Medical?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viveve Medical in the last year. There are currently 1 sell rating and 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Viveve Medical.
What are Wall Street analysts saying about Viveve Medical stock?
Here are some recent quotes from research analysts about Viveve Medical stock:
- 1. Maxim Group analysts commented, "Yesterday, after the Market close, VIVE reported 2Q19 revenue inline with our estimates adjusted for the preannouncement on July 22, 2019, but lower than consensus." (8/9/2019)
- 2. Mizuho analysts commented, "We expect these data readouts and milestone events will be the key drivers of VIVE shares in 2019/2020." (3/15/2019)
Has Viveve Medical been receiving favorable news coverage?
Media coverage about VIVE stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Viveve Medical earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Viveve Medical.
Who are some of Viveve Medical's key competitors?
Some companies that are related to Viveve Medical include IRIDEX (IRIX), Fc Global Realty (FCRE), Precision Optics (PEYE), Digirad (DRAD), ENDRA Life Sciences (NDRA), Non-Invasive Monitoring Systems (NIMU), CHF Solutions (CHFS), Nexeon Medsystems (NXNN), Vaso (VASO), Reshape Lifesciences (RSLS), Escalon Medical (ESMC), Trimedyne (TMED), Guided Therapeutics (GTHP), Echo Therapeutics (ECTE) and Magna-Lab (MAGAA).
What other stocks do shareholders of Viveve Medical own?
Who are Viveve Medical's key executives?
Viveve Medical's management team includes the folowing people:
- Mr. Scott C. Durbin, CEO & Director (Age 50)
- Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 61)
- Mr. Jim B. Robbins, VP of Fin. & Admin., Principal Accounting Officer and Principal Financial Officer (Age 55)
- Ms. Deborah A. Jorn, Sr. Advisor to the CEO & Director (Age 61)
- Mr. Martin Kerber, VP of Operations
When did Viveve Medical IPO?
(VIVE) raised $13 million in an initial public offering (IPO) on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.
How do I buy shares of Viveve Medical?
Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Viveve Medical's stock price today?
One share of VIVE stock can currently be purchased for approximately $5.09.
How big of a company is Viveve Medical?
Viveve Medical has a market capitalization of $7.48 million and generates $18.52 million in revenue each year. The company earns $-49,320,000.00 in net income (profit) each year or ($161.00) on an earnings per share basis. Viveve Medical employs 67 workers across the globe.View Additional Information About Viveve Medical.
What is Viveve Medical's official website?
How can I contact Viveve Medical?
Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]
MarketBeat Community Rating for Viveve Medical (NASDAQ VIVE)
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe VIVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
